Skip to content

Inspection prep notes · Laboratory

Sampling and reserve samples

Also called: sampling plan, reserve sample, retention sample

FDA looks less at whether samples were taken than at whether they represent the lot and batch and whether reserve samples are examined under a set procedure. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Reserve samples were not visually examined at the required interval

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least (b)(4) for evidence of deterioration.

FDA 483 · KDC/ONE Socal Laboratories, LLC · 2026-11-12 · View document

Specifically, your quality control unit has not established a procedure that governs the performance of visual inspection on reserve samples from representative sample lots at least once a year for evidence of deterioration.

FDA 483 · FinVector Oy · 2026-10-20 · View document

2Component and in-process samples were not representative

You failed to perform adequate identity testing of incoming components used in the manufacture of your OTC drug products. You also failed to collect representative samples from each lot of components.

FDA Warning Letter · SnugZ USA, Inc. · 2026-10-20 · View document

Sampling is not documented, and sampling techniques are not representative. For pH testing, your Senior Production Manager stated, “We just take a spatula and skim from the top and take it to QC.”

FDA 483 · Blossom Pharmaceuticals · 2026-10-22 · View document

3Finished product sampling was not set up to represent the batch

You lacked appropriate sampling and testing to ensure your drug products conform to appropriate standards of identity, strength, quality, and purity. For example, you failed to establish adequate procedures for finished drug product sampling to ensure adequate representation of each batch.

FDA Warning Letter · Creative Essences, Inc. · 2025-10-07 · View document

Your sampling plans prior to the release of your drug products are not sufficient to assure their quality. Specifically, your sampling and testing plan for SmileSense Fluoride Toothpaste and KT Tape Pain Relief Gel is not adequately justified to represent the quality attributes of the entire drug product batch.

FDA Warning Letter · Dynamic Blending Specialists, Inc. · 2025-07-08

4Incoming materials were not sampled and examined before use

Materials are accepted based on the suppliers certificate of analysis, without sampling and examination.

FDA 483 · Central Admixture Pharmacy Services Inc · 2025-12-03 · View document

Specifically, You firm failed to sample and perform identification testing to the components of each drug product prior to using it.

FDA 483 · Gascó Industrial Corporation · 2026-07-28 · View document

5A sampling plan or written sampling procedure was not in place

You failed to establish a sampling plan that assesses the sterility assurance of your product.

FDA 483 · Bello Bio LLC · 2026-10-27 · View document

Moreover, there are no written procedures in place for sampling products designated for retained storage.

FDA 483 · VitaCare Labs Inc. · 2026-10-23 · View document

Questions to check against your procedures

  1. Are reserve samples visually examined at the set interval for evidence of deterioration?
  2. Is there a procedure governing the visual examination of reserve samples?
  3. Are representative samples collected from each lot of components?
  4. Is the sampling method defined and is each sampling event documented?
  5. Has the finished product sampling plan been shown to represent the quality attributes of the entire batch?
  6. Are incoming materials sampled and examined rather than accepted on the supplier's certificate of analysis alone?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.